An Australian stem cell and regenerative medicine company

Science Publications

Vodyanik MA, Yu J, Zhang X, et al. A Mesoderm-Derived Precursor for Mesenchymal Stem and Endothelial Cells. Cell Stem Cell 2010;7(6):718-29.
Kelly K. Limitless starting materials for large-scale manufacture of MSCs – what does the future hold? Pharm Bioprocess. 2015;3:281-283.
Koch JM, D’Souza SS, Schwahn DJ, et al. Mesenchymoangioblast-derived mesenchymal stromal cells inhibit cell damage, tissue damage and improve peripheral blood flow following hindlimb ischemic injury in mice. Cytotherapy 2016;18:219–228.
Royce SG, Rele S, Broughton BRS, et al. Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease. FASEB J. 2017;31(9):4168-4178.
Kelly K. Next-generation cell-based therapies: the potential of IPSCs. Australasian Biotechnology. 2017;27(3):14-16.
Royce SG, Mao WY, Lim R, et al. iPSC- and mesenchymoangioblast-derived mesenchymal stem cells provide greater protection against experimental chronic allergic airways disease compared with a clinically used corticosteroid. FASEB J. 2019;15:fj201802307R.
Ozay EI, Vijayaraghavan J, Gonzalez-Perez G, et al. Cymerus™ iPSC-MSCs significantly prolong survival in a pre-clinical, humanized mouse model of Graft-vs-host disease. Stem Cell Res. 2019;35:101401.
Kelly K. Can iPSCs Address the Challenge of Maintaining Consistent Quality in Starting Materials Used in the Manufacture of Cell-Based Therapies? Cell & Gene Therapy Insights. 2019; 5(2), 227-232.
Khan MA, Alanazi F, Ahmed HA, et al. iPSC-derived MSC therapy induces immune tolerance and supports long-term graft survival in mouse orthotopic tracheal transplants. Stem Cell Res Ther. 2019;23;10(1):290.
Millar JE, Bartnikowski N, Passmore MR. Combined Mesenchymal Stromal Cell Therapy and Extracorporeal Membrane Oxygenation in Acute Respiratory Distress Syndrome. A Randomized Controlled Trial in Sheep. Am J Respir Crit Care Med. 2020 Aug 1;202(3):383-392.
Bloor AC, Patel A, Griffin JE, et al. Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nat Med. 2020;26(11):1720-1725.
Kelly K, Rasko JEJ. Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease. Front Immunol. 2021;12:761616.
Liu X, Robbins S, Wag X, et al. Efficacy and cost-effectiveness of Stem Cell injections for symptomatic relief and strUctural improvement in people with Tibiofemoral knee OsteoaRthritis: protocol for a randomised placebo-controlled trial (the SCUlpTOR trial). BMJ Open. 2021;11(11):e056382.
Thavapalachandran S, Le TYL, Romanazzo S. Pluripotent stem cell-derived mesenchymal stromal cells improve cardiac function and vascularity after myocardial infarction. Cytotherapy. 2021;23(12):1074-1084.
Romanazzo S, Kopecky C, Jiang S, et al. Biomaterials directed activation of a cryostable therapeutic secretome in induced pluripotent stem cell derived mesenchymal stromal cells. Tissue Eng Regen Med. 2022;16(11):1008-1018.
Results of the First Completed Clinical Trial of an iPSC-Derived Product: CYP-001 in Steroid-Resistant Acute GvHD
A comparative analysis of the MSC transcriptome: Human iPSC-derived MSCs and their tissue-derived counterparts